NovaBridge Biosciences Reports Strong Phase 1b Givastomig Data in Gastric Cancer, Advancing to Phase 2

summarizeSummary

NovaBridge Biosciences announced highly positive Phase 1b dose expansion data for givastomig in metastatic gastric cancer, demonstrating robust efficacy and a favorable safety profile, positioning it as a potential best-in-class therapy.

check_boxKey Events

• Positive Phase 1b Data

  Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, showed objective response rates of 77% (8 mg/kg) and 73% (12 mg/kg) in 1L HER2-negative metastatic gastric cancer.

• Promising Progression-Free Survival

  The 8 mg/kg dose achieved a median progression-free survival of 16.9 months, significantly outperforming current standard of care benchmarks.

• Favorable Safety Profile

  The combination therapy was well tolerated, with a safety profile comparable to standard of care. Immune-related gastritis, observed in 33% of patients, correlated with improved clinical outcomes.

• Advancing to Phase 2

  The company plans to initiate enrollment in a global, randomized Phase 2 study in Q1 2026, underscoring confidence in the drug's potential.

auto_awesomeAnalysis

This announcement represents a significant positive catalyst for NovaBridge Biosciences. The robust efficacy data, particularly the high objective response rates and impressive median progression-free survival, suggest that givastomig could offer a substantial improvement over existing treatments for metastatic gastric cancer. The favorable safety profile further strengthens its potential as a first-line therapy. Advancing to a global randomized Phase 2 study indicates strong clinical and regulatory confidence. Investors should view this as a major de-risking event for the company's lead asset, with the potential to capture a significant share of a multi-billion dollar market if subsequent trials are successful. The correlation between immune-related gastritis and improved outcomes is a unique and potentially beneficial finding.